Mechanisms of Cardiorenal Syndrome: From Molecular Pathways to Novel Therapeutics

Author(s):  
Tomoki Ichiki ◽  
Yang Chen ◽  
John C. Burnett
2012 ◽  
Vol 16 (3) ◽  
pp. 105-112 ◽  
Author(s):  
Irmgard Mühlberger ◽  
Konrad Mönks ◽  
Raul Fechete ◽  
Gert Mayer ◽  
Rainer Oberbauer ◽  
...  

2006 ◽  
Vol 44 (08) ◽  
Author(s):  
C Arnold ◽  
A Sosnowski ◽  
A Schmitt-Gräff ◽  
R Arnold ◽  
HE Blum

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1697-P
Author(s):  
YUTA HIRAIKE ◽  
HIRONORI WAKI ◽  
KANA MIYAKE ◽  
MISATO OGUCHI ◽  
TOSHIMASA YAMAUCHI ◽  
...  

2019 ◽  
Author(s):  
Bram Frohock ◽  
Jessica M. Gilbertie ◽  
Jennifer C. Daiker ◽  
Lauren V. Schnabel ◽  
Joshua Pierce

<div>The failure of frontline antibiotics in the clinic is one of the most serious threats to human health and requires a multitude of novel therapeutics and innovative treatment approaches to curtail the growing crisis. In addition to traditional resistance mechanisms resulting in the lack of efficacy of many antibiotics, most chronic and recurring infections are further made tolerant to antibiotic action by the presence of biofilms. Herein, we report an expanded set of 5-benzylidene-4-oxazolidinones that are able to inhibit the formation of Staphylococcus aureus biofilms, disperse preformed biofilms and in combination with common antibiotics are able to significantly reduce the bacterial load in a robust collagen-matrix model of biofilm infection.</div>


Sign in / Sign up

Export Citation Format

Share Document